News/ News/ R&D Roche gets first checkpoint inhibitor OK in breast cancer Phil Taylor breast cancer, Roche, Tecentriq 0 Comment Roche’s Tecentriq was the third PD-1/PD-L1 inhibitor to reach the market but is the first in class to Share X Roche gets first checkpoint inhibitor OK in breast cancer https://pharmaphorum.com/news/roche-gets-first-checkpoint-inhibitor-ok-in-breast-cancer/
News/ News/ R&D AbbVie/Roche seek first-line CLL use for Venclexta combo Phil Taylor AbbVie, CLL, Roche, Venclexta 0 Comment AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new Share X AbbVie/Roche seek first-line CLL use for Venclexta combo https://pharmaphorum.com/news/abbvie-roche-seek-first-line-cll-use-for-venclexta-combo/
News/ News/ Sales and Marketing Alnylam to seek approval for second RNAi drug Phil Taylor 0 Comment Alnylam thinks it has strong enough clinical data for its gene-silencing drug for rare disease acute hepatic porphyria Share X Alnylam to seek approval for second RNAi drug https://pharmaphorum.com/news/alnylam-approval-second-rnai-drug/
News/ News/ R&D/ Top stories Lilly claims fast FDA review for Emgality in cluster headache Phil Taylor cluster headache, Emgality, Lilly 0 Comment Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality Share X Lilly claims fast FDA review for Emgality in cluster headache https://pharmaphorum.com/news/lilly-claims-fast-fda-review-for-emgality-in-cluster-headache/
News/ News/ R&D Lilly to sell generic Humalog insulin at half price Phil Taylor Diabetes, Humalog, Lilly 0 Comment Eli Lilly has responded to criticism of high prices for insulin products in the US by launching a Share X Lilly to sell generic Humalog insulin at half price https://pharmaphorum.com/news/lilly-to-sell-generic-humalog-insulin-at-half-price/
News/ News/ R&D CHMP okays Sanofi’s Zynquista in type 1 diabetes Phil Taylor CHMP, Diabetes, Sanofi, Zynquista 0 Comment Sanofi has moved a step closer to getting its new diabetes therapy Zynquista approved in Europe, with a Share X CHMP okays Sanofi’s Zynquista in type 1 diabetes https://pharmaphorum.com/news/chmp-okays-sanofis-zynquista-in-type-1-diabetes/
News/ News/ Patients/ Top stories Sanders calls on FDA to allow low-cost rivals to $375k Catalyst drug Phil Taylor Bernie Sanders, Catalyst, Firdapse, rare disease 0 Comment US Senator Bernie Sanders says the FDA should allow pharmacies and generic manufacturers to make low-cost copies of Share X Sanders calls on FDA to allow low-cost rivals to $375k Catalyst drug https://pharmaphorum.com/news/sanders-calls-on-fda-to-allow-low-cost-rivals-to-375k-catalyst-drug/
Market Access/ News/ News/ Top stories Bayer completes US filing for prostate cancer drug darolutamide Phil Taylor Bayer, darolutamide, Prostate cancer 0 Comment Bayer has completed its rolling marketing application for prostate cancer drug darolutamide in the US, setting up possible Share X Bayer completes US filing for prostate cancer drug darolutamide https://pharmaphorum.com/news/bayer-completes-us-filing-for-prostate-cancer-drug-darolutamide/
News/ News/ R&D Celgene gets fast FDA review of Revlimid combo in lymphoma Phil Taylor Celgene, lymphoma, Revlimid 0 Comment Celgene is closing in on yet another new indication for its blood cancer blockbuster Revlimid, with the FDA Share X Celgene gets fast FDA review of Revlimid combo in lymphoma https://pharmaphorum.com/news/celgene-gets-fast-fda-review-of-revlimid-combo-in-lymphoma/
